Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI305 + cisplatin + pemetrexed + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of bevacizumab biosimilar IBI305, cisplatin (chemotherapy), pemetrexed (chemotherapy), and sintilimab (PD-1 inhibitor). IBI305 is a bevacizumab biosimilar that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis by blocking VEGF-A from binding to its receptors. Sintilimab is a PD-1 inhibitor that enhances T-cell immune responses against tumor cells. This combination is being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations who have progressed on EGFR tyrosine kinase inhibitors.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on IBI305 + cisplatin + pemetrexed + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI305 + cisplatin + pemetrexed + sintilimab.